TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-159605 | Others
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Targeted Therapy With B Cell Maturation Antigen (Bcma) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET
7.1 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA TARGETED THERAPY WITH B CELL MATURATION ANTIGEN (BCMA) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Transposagen Biopharmaceuticals
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Sutro Biopharma
16.3 Malin Corporation
16.4 Eureka Therapeutics
16.5 firstVentury Equity
16.6 Five Prime Therapeutics
16.7 Credit Suisse Securities
16.8 Dana-Farber Cancer Institute
16.9 Deerfield Partners
16.10 Onyx Pharmaceuticals
16.11 Juno Therapeutics
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeBispecific antibody
Antibody drug conjugate
Chimeric antigen receptor T cells
By Application
liver cancer
Respiratory cancer
Brain cancer
Other applications
Companies
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.